Cargando…
Cost–utility analysis of mogamulizumab in advanced mycosis fungoides and Sézary syndrome cutaneous T-cell lymphoma
AIM: This study assessed the cost–utility of mogamulizumab, a novel monoclonal antibody, versus established clinical management (ECM) in UK patients in previously treated advanced mycosis fungoides (MF)/Sézary syndrome (SS). MATERIALS & METHODS: Lifetime partitioned survival model based on overa...
Autores principales: | Muszbek, Noemi, Remak, Edit, Xin, Qian, McNamara, Linda, Jones, Trefor |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Becaris Publishing Ltd
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10508303/ https://www.ncbi.nlm.nih.gov/pubmed/37338181 http://dx.doi.org/10.57264/cer-2023-0028 |
Ejemplares similares
-
Overall survival in the UK in mycosis fungoides or Sézary syndrome cutaneous T-cell lymphoma: comparative effectiveness of mogamulizumab versus current standard of care
por: Hawkins, Neil, et al.
Publicado: (2023) -
Impact of blood involvement on efficacy and time to response with mogamulizumab in mycosis fungoides and Sézary syndrome
por: Beylot‐Barry, Marie, et al.
Publicado: (2022) -
PB2345: MOGAMULIZUMAB IN MYCOSIS FUNGOIDES AND SÈZARY SYNDROME: AN ITALIAN SINGLE CENTER EXPERIENCE
por: Simula, Maria Pina, et al.
Publicado: (2023) -
The utility of bexarotene in mycosis fungoides and Sézary syndrome
por: Panchal, Manisha R, et al.
Publicado: (2015) -
Mycosis fungoides and Sézary syndrome
por: Jonak, Constanze, et al.
Publicado: (2021)